Peptide Synthesis Market

The peptide synthesis market is projected to reach USD 1.54 billion by 2031 from an estimated USD 0.98 billion in 2026, at a CAGR of 9.5% during the forecast period. Market growth is driven by increasing peptide-based drug discovery and development, rising adoption of GLP-1 and other peptide therapeutics, and growing demand for custom peptides in pharmaceutical, biotechnology, diagnostic, and academic research. Increasing use of automated and high-throughput peptide synthesizers, advanced purification technologies, and recurring consumption of protected amino acids, resins, coupling reagents, and other synthesis consumables is further supporting market growth. Demand for complex, modified, cyclic, and conjugated peptides is also encouraging adoption of specialized synthesis and analytical solutions.

The global peptide synthesis market is moderately consolidated, with Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), and GenScript Biotech Corporation (China) among the prominent participants. Competition centers on broad peptide synthesis portfolios, synthesis speed and throughput, reagent quality, purification efficiency, analytical capabilities, complex peptide synthesis, and global service availability. Market participants are pursuing product launches, technology enhancements, portfolio expansions, partnerships, and geographic expansions to strengthen their positions and address increasing demand for efficient and scalable research and development workflows.

To know about the assumptions considered for the study download the pdf brochure

In June 2025, CEM Corporation (US) launched the Prodigy 2.0 preparative HPLC system for synthetic peptide purification. The system enables elevated-temperature purification and supports replacement of acetonitrile with ethanol.

In September 2025, Phenomenex, a Danaher Corporation company (US), launched the Biozen dSEC-1 size-exclusion chromatography column for midsize biotherapeutics, including peptides. The product is designed to improve aggregate and structural-variant characterization and supports analytical workflows for peptide therapeutics, including GLP-1-class molecules.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. is a leading player in the peptide synthesis market, offering synthesis chemicals, custom peptide services, purification solutions, and analytical technologies. Its portfolio includes coupling and deprotection reagents, cleavage agents, solvents, and custom synthesis of standard, isotope-labeled, and library peptides. The company’s strong market position is supported by its broad global distribution network, recurring consumables business, and ability to offer integrated solutions across synthesis, purification, and peptide characterization. Its portfolio serves pharmaceutical, biotechnology, proteomics, and academic research applications.

Merck KGaA (Germany)

Merck KGaA is a prominent supplier in the peptide synthesis market through its Sigma-Aldrich and Novabiochem portfolios. The company offers protected amino acids, synthesis resins, coupling reagents, linkers, deprotection reagents, and specialized building blocks for solid-phase peptide synthesis. Its competitive position is supported by an extensive reagent portfolio, strong quality standards, and recurring consumables demand across pharmaceutical, biotechnology, and academic laboratories. Merck also offers specialized products for cyclic, branched, and modified peptides, strengthening its presence in complex peptide synthesis workflows.

Agilent Technologies, Inc. (US)

Agilent Technologies, Inc. is a key provider of purification and analytical solutions used in peptide synthesis workflows. Its portfolio includes HPLC and UHPLC systems, LC/MS platforms, preparative chromatography solutions, columns, and related consumables for peptide purification and characterization. The company supports therapeutic peptide workflows, including GLP-1-based molecules, through separation, impurity analysis, and identity confirmation solutions. Agilent’s market position is supported by its strong chromatography expertise, large installed base, and integrated analytical technologies serving pharmaceutical and biopharmaceutical laboratories.

GenScript Biotech Corporation (China)

GenScript Biotech Corporation is a leading custom peptide synthesis service provider, offering standard peptides, modified peptides, peptide libraries, neoantigen peptides, and peptide conjugates. Its proprietary PepPower platform supports rapid synthesis of complex peptide sequences, while its capabilities include cyclization, labeling, conjugation, and other structural modifications. GenScript’s market position is supported by its broad customer base, high-throughput synthesis capacity, strong modification expertise, and integrated peptide design and ordering capabilities. Its services are widely used across drug discovery, immunology, proteomics, and diagnostic research.

Kaneka Corporation (Japan)

Kaneka Corporation (Japan) operates in the peptide synthesis market mainly through Kaneka Eurogentec S.A. and AnaSpec. The group provides custom synthesis of standard and complex peptides, including cyclic, stapled, disulfide-bridged, labeled, glycosylated, and isotope-labeled peptides, along with peptide libraries. Its competitive position is supported by expertise in difficult peptide sequences, broad modification capabilities, and established operations across Europe and North America. AnaSpec serves as a key peptide synthesis center for the group, supporting pharmaceutical, biotechnology, diagnostic, and academic research customers.

Market Ranking

The peptide synthesis market is moderately consolidated, with Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), GenScript Biotech Corporation (China), and Kaneka Corporation (Japan) collectively accounting for 49–54% of the global market in 2025. Thermo Fisher Scientific holds a strong position through its broad portfolio of peptide synthesis reagents, custom peptide services, purification solutions, and analytical technologies. Merck KGaA benefits from its extensive Sigma-Aldrich and Novabiochem portfolios of protected amino acids, resins, coupling reagents, and specialized peptide synthesis building blocks. Agilent Technologies maintains a strong presence in peptide purification and characterization through its HPLC, UHPLC, LC/MS, preparative chromatography, and related consumables portfolio. GenScript Biotech is a major custom peptide synthesis provider, with capabilities in modified peptides, peptide libraries, conjugates, and complex sequences. Kaneka Corporation, primarily through Kaneka Eurogentec and AnaSpec, strengthens its position through custom synthesis capabilities for standard, modified, cyclic, labeled, and other specialized peptides.

The remaining share of the market, approximately 46–51%, is held by Sartorius AG (Germany), Biotage AB (Sweden), Bachem Holding AG (Switzerland), CEM Corporation (US), Bio-Synthesis, Inc. (US), Biosynth (Switzerland), CSBio (US), and other specialized suppliers. Competition is driven by synthesis efficiency, peptide purity, sequence complexity, reagent and building-block quality, automation, turnaround time, customization capabilities, and technical support. Specialized companies continue to compete effectively across peptide synthesizers, protected amino acids, resins and reagents, custom peptide synthesis, peptide libraries, modified peptides, and purification and analytical solutions.

Related Reports:

Peptide Synthesis Market by Instruments (Synthesizers, Purification, Lyophilizers, Analytical), Reagents (Amino Acids, Resins), Technique (Chemical, Biological), Services (Custom Synthesis, Modification), Application, End User - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]